Japan and Western drugmakers launch $1bn fund against superbugs
Takeda, Glaxo and Amgen among 23 names uniting to fight antibiotic resistance
A magnified image of methicillin-resistant Staphylococcus aureus bacteria: drug-resistant diseases kill about 700,000 people a year across the world.
TOKYO -- Drugmakers from Japan, the U.S. and Europe have announced a more than $1 billion fund to invest in startups developing treatments for antibiotic-resistant infections.
The 23 companies include Eisai, Shionogi, Daiichi Sankyo, Takeda Pharmaceutical and Chugai Pharmaceutical from Japan, as well as Amgen and Eli Lilly from the U.S. and Novartis and GlaxoSmithKline from Europe. The World Health Organization and the European Investment Bank also form part of the effort.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapterFind out more
Free access for everyone - Sep. 30